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Background: The benefit of neoadjuvant chemoradiotherapy in oesophageal cancer has been extensively
studied but data on survival are still equivocal.
Objective: To assess the effectiveness of chemoradiotherapy followed by surgery in the reduction of
mortality in patients with resectable oesophageal cancer.
Methods: Computerised bibliographic searches of MEDLINE and CANCERLIT (1970–2002) were
supplemented with hand searches of reference lists.
Study selection: Studies were included if they were randomised controlled trials (RCTs) comparing
preoperative chemoradiotherapy plus surgery with surgery alone, and if they included patients with
resectable histologically proven oesophageal cancer without metastatic disease. Six eligible RCTs were
identified and included in the meta-analysis.
Data extraction: Data on study populations, interventions, and outcomes were extracted from each RCT
according to the intention to treat method by three independent observers and combined using the
DerSimonian and Laird method.
Results: Chemoradiotherapy plus surgery compared with surgery alone significantly reduced the three
year mortality rate (odds ratio (OR) 0.53 (95% confidence interval (CI) 0.31–0.93); p = 0.03) (number
needed to treat = 10). Pathological examination showed that preoperative chemoradiotherapy down-
staged the tumour (that is, less advanced stage at pathological examination at the time of surgery)
compared with surgery alone (OR 0.43 (95% CI 0.26–0.72); p = 0.001). The risk for postoperative
mortality was higher in the chemoradiotherapy plus surgery group (OR 2.10 (95% CI 1.18–3.73);
p = 0.01).
Conclusions: In patients with resectable oesophageal cancer, chemoradiotherapy plus surgery significantly
reduces three year mortality compared with surgery alone. However, postoperative mortality was
significantly increased by neoadjuvant chemoradiotherapy. Further large scale multicentre RCTs may
prove useful to substantiate the benefit on overall survival.
W
orldwide, oesophageal cancer ranks fifth in mortal-
ity rate among tumour sites.1 The European
weighted survival, calculated from the pool of all
cancer registries, was 33% at one year and 10% at five years.2
The three year survival rate of patients with local-regional
oesophageal cancer who have undergone curative resection
remains low (approximately 20%) with a high postoperative
mortality rate ranging from 3% to 10%.3–6 Therefore,
oesophageal cancer is a treatable but rarely curable disease.
Improved and standardised surgical techniques as well as
advances in supportive care have contributed to an increase
in the rate of curative resection.5 Nevertheless, a plateau in
the effectiveness of surgical resection may well have been
reached and further improvement in survival from a single
modality approach seems unlikely.6
Recently, neoadjuvant therapy has become the focus of
interest in an effort to prolong survival and reduce recurrence
rates in patients with oesophageal cancer. Studies have
indicated that preoperative radiotherapy increases the rate of
resectability but a meta-analysis of these randomised
controlled trials (RCTs) failed to show a statistically
significant benefit on survival.7 Preoperative chemotherapy
trials have shown conflicting results even in the most recent
large scale RCTs.8–11 The potential activity of chemotherapy
against micrometastases as well as the radiosensitising
properties of some chemotherapeutic agents has led to the
treatment of patients with a combination of radiotherapy and
chemotherapy. Since the first RCT of preoperative chemor-
adiotherapy (CRT) appeared in 1992,12 several RCTs have
been published.13–22 The results of these trials are inconclusive
or conflicting because of the relatively small samples.
Additionally, it is difficult to draw general conclusions from
them because of differences in patient characteristics and
treatment regimens. A recently published RCT performed at
the University of Michigan17 concluded that preoperative CRT
did not improve survival compared with surgery alone. The
aim of this systematic review and meta-analysis is to
determine if there is a benefit of preoperative CRT compared
with surgery alone.
METHODS
Selection of randomised trials
The primary source of the reviewed studies was MEDLINE
and CANCERLIT, including non-English sources, with the
following medical subject headings: oesophageal cancer,
chemoradiotherapy, radiotherapy, chemotherapy, RCT, ran-
domised, and clinical trial. The search included literature
published through to December 2002. The computer search
was supplemented with manual searches of reference lists for
all available review articles, primary studies, abstracts from
meetings, and bibliographies of books. We have contacted the
investigators of an Australian trial, which was reported twice
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as an abstract,19 20 in order to obtain data on randomisation
and survival.
Studies were included in the meta-analysis if they were
RCTs comparing preoperative CRT plus surgery with surgery
alone, if they included patients with resectable histologically
proven squamous cell carcinoma or adenocarcinoma of the
oesophagus without metastatic disease, and if mortality was
assessed as an outcome measure of the effect of the
treatment. Among the 11 studies reviewed, six RCTs met
the inclusion criteria.12–17 Five studies18–22 were excluded
because they were published as a preliminary report or
abstract18 21 22 and subsequently published as a final paper, or
because they were published as an abstract, not reporting
survival data.19 20 As all the trials reported as abstracts21 22
were subsequently published as full papers, this meta-
analysis included only peer reviewed reports.
This meta-analysis was performed according to the
QUOROM statement.23
Review of the trials
The trials were first reviewed using a list of predefined
pertinent issues that concerned the characteristics of patients
and treatments. To assess the methodological quality of RCTs,
the two domains of blinding and handling withdrawals and
dropouts, using the definitions given by Nicolucci and
colleagues,24 were used, as suggested by Ju¨ni and collea-
gues.25 Each RCT was evaluated and classified by three
independent investigators (FF, AV, DDB). Discrepancies
among reviewers were infrequent (overall interobserver
variations ,10%), and were resolved by discussion.
Statistical methods
The crude rate of three year overall mortality was assessed as
a measure of treatment effect. These data were available in
three RCTs.15–17 In the remaining three trials12–14 we used the
Kaplan-Meier estimates of the three year mortality in the
treated and control groups reported in the text. Moreover, to
assess the downstaging effect of CRT (that is, the probability
of having a less advanced stage of the disease at pathological
examination at the time of surgery), we separated patients
with negative nodes and patients with positive nodes on
pathological examination at the time of surgery. As a
measure of treatment benefit, we compared the proportion
of patients observed in the treated and control groups who
were classified as stage 0, 1, or 2a according to the American
Joint Committee on Cancer.26 Downstaging by chemora-
diotherapy was also used as a measure of treatment effect on
pathological response at the time of surgery. Furthermore, we
analysed the 90 day inhospital mortality (postoperative
mortality).
Evaluation of therapeutic effectiveness was performed by
an intention to treat method. When not reported in the trial,
response rate, according to the intention to treat method, was
calculated. The number of patients who discontinued their
original irradiation regimen because of side effects was also
recorded. To combine results from individual trials, we used
the proportion of events observed in the treated and control
groups. With these observed proportions of events, the odds
ratio (OR) was computed for each trial.
The overall OR among the frequencies of the events in both
the chemoradiotherapy plus surgery group and the surgery
alone group was calculated with models based on both fixed
effects and random effects assumptions. In addition to
within study variance, the random effects model considers
heterogeneity among studies. Because of the different clinical
settings and groups of subjects analysed and because the
tests for heterogeneity lack statistical power due to the few
studies included in this meta-analysis, we have presented the
results of random effects models, according to DerSimonian
and Laird.27 The 95% confidence interval (95% CI) of the odds
ratio was also calculated. The overall OR was tested for
significance using a Mantel-Haenszel x2 test.28
Moreover, we in turn excluded each study to ensure that
no single study would be solely responsible for the
significance of any result (so-called robust analysis). All our
analyses were computed using Metaview 4.0. The number of
patients needed to treat (NNT) to prevent one death, and the
number of patients needed to harm (NNH) to prevent one
death by postoperative mortality, which both derive from the
inverse of the risk difference, were also used as a measure of
treatment benefit and safety.29
To improve the comparability of the different therapeutic
regimens and to assess the relationship between radiation
dose and survival benefit, the biologically effective dose
(BED), corrected for time of the various radiation schedules,
was estimated.30 In the Scandinavian trial,12 three different
treatment arms were compared with the same surgery arm as
the control. We included in the analysis only the chemor-
adiation treatment arm of this RCT, using effect size
estimates calculated from observations on that measure.
Therefore, the statistical analysis used only independent
estimators of effect size.31
Subgroup analyses were used to explore and explain the
diversity among results of different studies. We used two
stratifying variables: adenocarcinoma versus squamous cell
carcinoma and BED .35 versus BED (35. A x2 test for
interaction32 was used to examine whether the effect of
treatment varied significantly between subgroups.
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Table 1 Patients characteristics of trials included in the meta-analysis
Study (reference)*
Accrual
period (y)
Patients randomised
(n)
Male
(%)
Mean age
(y)
Histology (%)
Preoperative stage (% of patients)SCC ADENO
1 Nygaard et al12 1983–88 CRT+S 53 70 60.1 100 0 I–II (100)
S 50 75 61.4 100 0 I–II (100)
2 Le Prise et al13 1988–91 CRT+S 41 93 56 100 0 I (12.2); II (65.8); not specified (22)
S 45 93 59 100 0 I (35.5); II (55.6); not specified (8.9)
3 Apinop et al14 1986–92 CRT+S 35 80 59.6 100 0 IIb (17.1); III (82.9)
S 34 76 59.8 100 0 IIb (14.8); III (82.3); not specified (5.9)
4 Walsh et al15 1990–95 CRT+S 58 67 65 0 100 NR
S 55 80 65 0 100 NR
5 Bosset et al16 1989–95 CRT+S 151 90 57 100 0 I (15.9); IIa (56.9); IIb (21.8) not specified (8)
S 146 96 57 100 0 I (17.1); IIa (56.2); IIb (21.9) not specified (4.8)
6 Urba et al17 1989–94 CRT+S 50 84 62 26 74 I–IIa (60); IIb–III (40)
S 50 86 64 24 76 I–IIa (56); IIb–III (44)
*For expansion of the study names, see corresponding reference.
CRT+S, chemoradiotherapy plus surgery; S, surgery; SCC, squamous cell carcinoma; ADENO, adenocarcinoma; NR, not reported.
2 Fiorica, Bona, Schepis, et al
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Source of support
This meta-analysis was entirely supported by the author’s
respective institutions.
RESULTS
Features of the RCTs
The main features of the trials included in the meta-analysis
are shown in table 1. The six RCTs included 764 patients, 385
of whom received CRT before surgery. The percentage of
males ranged from 78%14 to 93%.13 16 The criteria for inclusion
were uniform in all but one RCT, which included only
patients with locally advanced but otherwise operable
tumours.14 Only two studies12 16 were multicentre trials. The
sample size of each RCT varied greatly, ranging from 6914 to
29716 patients. No adequate blinding was used in two
trials12 14 and the method of randomisation was not clearly
reported in the remaining four studies.12–14 Three studies12–14
did not clearly define criteria for handling withdrawals.
The preoperative staging procedures were uniform in all
RCTs. In four RCTs12 14 16 17 all patients underwent computed
tomography (CT) while in the study of Le Prise and
colleagues,13 and in the Irish trial15 CT was performed in
selected patients only. Data on preoperative staging of the
tumour were similar in all RCTs, except the small study of
Apinop and colleagues14 in which stage I oesophageal cancer
was excluded (table 1). In all RCTs no significant differences
were found in the preoperative stage of the tumour between
treated and control groups.
A transthoracic resection was performed in all RCTs but
one17 in which a transhiatal oesophagectomy was employed.
The rate of resection (curative or palliative) reported in all
RCTs ranged from 82%12 to 97%.14 17 The proportion of
patients who underwent resection classified as curative
(defined by the surgeon as margins of the resected tissue
free of tumour) was reported in only three RCTs,12 13 17
ranging from 46% to 97%.
Pathological stage was assessed in all RCTs at the time of
operation according to the American Joint Committee on
Cancer. The rate of pathological stage III oesophageal cancer
in patients treated by surgery alone was comparable in all
RCTs, ranging from 50%16 to 78%.15 In four RCTs,12–14 16 only
patients with squamous cell carcinoma were included, while
in the study by Walsh and colleagues15 all subjects had
adenocarcinoma, and in the RCT by Urba and colleagues17
patients with either squamous cell carcinoma or adenocarci-
noma were included (table 1).
The therapeutic regimens of RCTs included in the meta-
analysis are shown in table 2. Considerable heterogeneity was
observed both in radiotherapy and chemotherapy protocols
among the studies. A large variability in irradiation schedules
between trials was found in: (a) the total dose, ranging
between 2013 and 4517 Gray (Gy); (b) the daily dose, ranging
between 1.7512 and 3.7016 Gy; and (c) the number of
fractions, ranging between 1016 and 3017 given over 24 and
21 days, respectively.
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Table 2 Therapeutic regimen of all trials included in the meta-analysis
Study (reference)`
Radiotherapy Chemotherapy Surgery
Total
dose (Gy)
Fractions
(No/days)
Daily dose
(Gy)
BED
(Gy)
BED corrected
by time (Gy) Drugs
Dosage
(mg/m2)
Schedules
(day)
Interval between end of
irradiation and surgery
(weeks)
1 Nygaard et al12 35 20/28 1.75 41.12 26.7* CDDP 20 1–5; 15–19 3
BLM 5
2 Le Prise et al13 20 10/12 2 24 17.8* CDDP
5FU 100 1; 21 2.5
600 2–5; 22–25
3 Apinop et al14 40 20/28 2 48 33.6* CDDP 100 1; 29 4
5FU 1000 1–4;29–32
4 Walsh et al15 40 15/21 2.67 50.7 42.6 CDDP 75 7;42 2
5FU 15 mg/kg 1–5;36–40
5 Bosset et al16 37 10/24 3.7 50.7 38.4* CDDP 80 0–2;19–21 2–4
6 Urba et al17 45 30/21 1.562 51.7 43.6
adenoca.
CDDP 20 1–5;17–21 3
40.9*
squamo.
5FU 300 1–21
VNB 1 1–4;17–20
*Tpot squamo = 4.5 days
33; Tpotadeno = 6 days,
33
a= 0.3
BED, biological equivalent dose; CDDP, cisplatin; BLM, bleomycin; 5-FU, 5-fluorouracil; VNB, vinblastin.
`For expansion of the study names, see corresponding reference.
Nygaard et al12
Apinop et al14
Le Prise et al13
Walsh et al15
Bosset et al16
Urba et al17
44/53
26/35
33/41
39/58
94/151
34/50
45/50
27/34
39/45
52/55
97/146
42/50
13.4
14.1
13.6
11.7
30.2
17.1
0.54 [0.17, 1.75]
0.75 [0.24, 2.31]
0.63 [0.20, 2.02]
0.12 [0.03, 0.43]
0.83 [0.52, 1.34]
0.40 [0.15, 1.06]
Total (95% Cl)
Test for heterogeneity χ2=8.84 df=5 p=0.12
Test for overall effect z=_2.41 p=0.02
270/388 302/380 100.0 0.53 [0.31, 0.89]
Study
Treatment
(n/N)
Control
(n/N)
OR
(95% Cl random)
OR
(95% Cl random)
Weight
(%)
0.01 0.1 1 10 100
Better CRT+surgery Better surgery
Figure 1 Meta-analysis of six randomised controlled trials of preoperative chemoradiotherapy (CRT) for resectable oesophageal carcinoma using a
random effects model. The odds ratio (OR) and 95% confidence interval (CI) for the effect of treatment on three year overall mortality are shown on a
logarithmic scale. Studies are arranged by publication year.
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Variability in the chemotherapy protocol between trials
was found in: (a) the number and type of chemotherapeutic
agents administered in combination with cisplatin; and (b)
the dose and scheduling of chemotherapeutic drugs (table 2).
In one RCT,12 chemotherapy and radiotherapy were given
sequentially with radiotherapy starting three weeks after
completion of chemotherapy. In the remaining five RCTs,
CRT was given simultaneously (concomitant strategy) with
daily chemotherapy14 15 17 or with intermittent chemother-
apy.13 16
Overall mortality
The effect of adjuvant CRT on overall mortality (six RCTs: 764
patients, 573 deaths) is shown in fig 1. Although the effect of
treatment on total mortality favoured CRT in all the six trials,
a statistically significant difference was observed in only
one.15 However, the pooled estimate of the treatment effect
was statistically significant (OR 0.53 (95% CI 0.31–0.92);
z =22.23; p = 0.03) (NNT = 10). Similar results were
obtained when a fixed effect model was used (OR 0.61
(95% CI 0.43–0.85); z =22.89; p = 0.004).
Robust analysis showed that the five trials remaining after
exclusion of either the trial by Walsh and colleagues15 or by
Urba and colleagues17 lost statistical significance for overall
mortality (excluding the trial by Walsh: OR 0.73 (95% CI
0.51–1.05), z =21.68 p = 0.093; excluding the trial by Urba:
OR 0.55 (95% CI 0.29–1.06), z =21.78; p = 0.074).
We performed subgroup analyses to evaluate whether
there was evidence of a different effect of CRT in predefined
subgroups of patients. For overall mortality, the pooled OR
was statistically significant in patients with adenocarcinoma
(OR 0.24 (95% CI 0.07–0.78); z =22.36, p = 0.018) but not in
those with squamous cell carcinoma (OR 0.81 (95% CI 0.55–
1.19); z =21.07, p = 0.29), with a significant interaction (x2
for interaction = 7.79; 1 df; p = 0.0055). When grouped by
BED, analysis showed that the pooled OR was 0.40 (95% CI
0.13–1.22, z =21.61, p = 0.11) in patients who received a
BED greater than 35 Gy and 0.64 (95% CI 0.33–1.24,
z =21.32, p = 0.19) in those who received a BED of 35 Gy
or less without a significant interaction (x2 for interac-
tion = 0.03; 1 df; p = 0.86).
Downstaging effect
A total of four RCTs12 13 15 16 involving 573 patients were
available for evaluating the downstaging effect of CRT (fig 2).
Patients who received preoperative CRT were less likely to
have an advanced stage of cancer at pathological examina-
tion than were controls. Preoperative CRT was superior to
surgery alone in all studies, reaching statistical significance in
two RCTs.15 16 The pooled OR was 0.43 (CI 0.26–0.72,
z =23.26, p = 0.001) (NNT = 5). Similar results were
obtained when a fixed effect model was used (OR 0.44
(95% CI 0.31–0.62); z =24.69, p = 0.00001). In all the robust
analyses the pooled estimate of the treatment effect was
significant.
Compliance, postoperative complications, and
mortality
Compliance with treatment was generally satisfactory. Forty
five (11.7%) of 385 patients undergoing adjuvant treatment
did not complete the planned protocol, and only 25 (6.5%)
required a reduction in chemotherapeutic (21 patients) or
irradiation dose (four patients).
The overall rate of postoperative adverse events was 39.4%
(137/348) in the CRT group and 34.3% (123/358) in the
surgery alone group (x2 = 1.90; df = 1; p = 0.16). The three
most frequent adverse events were respiratory complications
(19.9%), heart failure (6.9%), and anastomotic leak (6.9%).
The risk of postoperative mortality (within 90 days) was
higher in the CRT group in five RCTs,12 13 15 16 reaching
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Nygaard et al12
Le Prise et al13
Walsh et al15
Bosset et al16
24/50
24/41
26/58
77/143
27/42
30/45
45/55
98/139
21.8
20.7
21.3
36.2
0.51 [0.22, 1.19]
0.71 [0.29, 1.70]
0.18 [0.08, 0.43]
0.49 [0.30, 0.80]
Total (95% Cl)
Test for heterogeneity χ2=5.55 df=3 p=0.14
Test for overall effect z=_3.26 p=0.001
151/292 200/281 100.0 0.43 [0.26, 0.72]
Study
Treatment
(n/N)
Control
(n/N)
OR
(95% Cl random)
OR
(95% Cl random)
Weight
(%)
0.1 0.2 1 5 10
Better CRT+surgery Better surgery
Figure 2 Meta-analysis of four randomised controlled trials of preoperative chemoradiotherapy (CRT) for resectable oesophageal carcinoma using a
random effects model. The odds ratio (OR) and 95% confidence intervals (CI) for the effect of treatment on downstaging (defined as a lower probability
to have an advanced stage of cancer at pathological examination at the time of surgery) are shown on a logarithmic scale. Studies are arranged by
publication year.
Nygaard et al12
Apinop et al14
Le Prise et al13
Walsh et al15
Bosset et al16
Urba et al17
8/34
5/26
3/32
5/51
17/138
1/47
5/38
5/34
3/41
2/55
5/137
2/50
21.8
17.8
11.8
11.6
31.3
5.6
2.03 [0.59, 6.95]
1.38 [0.35, 5.39]
1.31 [0.25, 6.97]
2.88 [0.53, 15.56]
3.71 [1.33, 10.36]
0.52 [0.05, 5.95]
Total (95% Cl)
Test for heterogeneity χ2=3.25 df=5 p=0.66
Test for overall effect z=2.53 p=0.01
39/328 22/355 100.0 2.10 [1.18, 3.73]
Study
Treatment
(n/N)
Control
(n/N)
OR
(95% Cl random)
OR
(95% Cl random)
Weight
(%)
0.01 0.1 1 10 100
Worse CRT+surgeryWorse surgery
Figure 3 Postoperative mortality. Meta-analysis of six randomised controlled trials of preoperative chemoradiotherapy (CRT) for resectable
oesophageal carcinoma using a random effects model. The odds ratio (OR) and 95% confidence interval (CI) for the effect of treatment on postoperative
mortality (90 day inhospital mortality) are shown on a logarithmic scale. Studies are arranged by publication year.
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statistical significance in one of these five trials16 in which a
high dose per fraction radiation (3.7 Gy) was given (fig 3).
Combining the data from the six RCTs, which included 683
patients, showed a significant effect of CRT on postoperative
mortality (OR 2.10 (95% CI 1.18–3.73); z = 2.53, p = 0.01)
(NNH = 25). Similar results were obtained when a fixed
effect model was used (OR, 2.15 (95% CI 1.23–3.74); z = 2.69;
p = 0.007).
Robust analysis showed a loss of significance for post-
operative mortality (OR 1.62 (95% CI 0.81–3.24); z = 1.36,
p = 0.17) once the largest trial by Bosset and colleagues16 was
excluded. Moreover, sensitivity analysis performed by
excluding the two RCTs14 15 with a fraction per day dose .2
Gy showed a similar effect size as the robust analysis without
statistical significance (OR 1.44 (95% CI 0.67–3.08) z = 0.94,
p = 0.35).
DISCUSSION
This study has investigated the key clinical question of
whether preoperative CRT is efficacious in treating oesopha-
geal cancer. To our knowledge, no consensus on the type of
patients amenable to chemoradiotherapy has been reached to
date.
This meta-analysis of data from six RCTs showed that in
resectable oesophageal cancer, preoperative CRT significantly
improves three year survival versus surgery alone
(NNT = 10). Moreover, an impressive reduction in the rate
of advanced oesophageal cancer (stages IIb and III) was
observed in almost all trials at the time of surgery (down-
staging) (NNT = 5). Although there is evidence that chemor-
adiotherapy significantly increases postoperative mortality
(NNH = 25), fewer patients need to be treated to benefit from
the treatment long term than need to be treated to be harmed
immediately post surgery.
The effect of preoperative CRT on overall survival is much
more pronounced and statistically significant in patients with
adenocarcinoma, that is now more prevalent than squamous
cell carcinoma in the USA33 and Western Europe,34 with most
tumours located in the distal oesophagus. However, the
sample size of this subgroup analysis was small (data
obtained from only two trials), and caution must be exercised
when interpreting results from this exploratory analysis.
Nevertheless, our data strongly indicate the need for
designing future trials considering the clinical difference
between adenocarcinoma and squamous cell carcinoma and
its potential influence on patient response to therapy.
Furthermore, the current staging system for oesophageal
cancer is mostly applicable to patients with squamous cell
carcinomas of the upper and middle thirds of the oesopha-
gus. To better evaluate the differential therapeutic response
to CRT of patients with adenocarcinoma, this staging system
should be adapted to better fit patients with adenocarcinoma,
who most often present with distal oesophageal and gastro-
oesophageal junction tumours. In particular, patients with
regional and/or coeliac axis lymphadenopathy should not
necessarily be considered to have unresectable disease due to
metastases.
Many efforts have been made to identify the optimal
chemoradiotherapy regimen that would increase the cost
effectiveness of therapy. There was considerable variation in
the irradiation procedures, suggesting that worldwide
accepted and standardised radiation techniques are needed
to obtain comparable data on the efficacy and safety profile,
particularly regarding the total and daily dose of radiation
and the dose of cisplatin administered. We found that higher
postoperative mortality was observed in the two RCTs15 16 in
which a fraction per day dose .2 Gy was delivered.
Furthermore, the risk of postoperative mortality was higher
in the RCT by Bosset and colleagues16 in which a high dose of
both radiotherapy and cisplatin was administered. On the
other hand, the hyperfractionated irradiation schedule
combined with a low dose of cisplatin administered in the
trial by Urba and colleagues17 was more safe than the others,
suggesting that a reduction of late effect achieves the best
cost/effectiveness ratio. Finally, the trial by Urba and
colleagues17 was the only one in which a transhiatal
oesophagectomy was employed.
We believe the available information is inadequate to
determine whether a concomitant regimen of chemora-
diotherapy is better than induction chemotherapy followed
by radiotherapy. Among the trials analysed, only that of
Nygaard and colleagues12 delivered radiotherapy three weeks
after completion of chemotherapy. The trials of Le Prise and
colleagues13 and Bosset and colleagues16 delivered radio-
therapy within one week after chemotherapy (intermittent
chemotherapy) while CRT was administered simultaneously
in the remaining three RCTs. Two of these three RCTs (by
Walsh and Urba) showed the highest therapeutic benefit.
However, it has been postulated that induction chemother-
apy may be more effective than the concomitant approach on
the premise that areas of radiochemotherapy may harbour
treatment resistant tumour cells and that combined toxic
effects may limit the dose of drugs that can be given. Firm
conclusions on the results of direct comparisons between
chemoradiotherapy delivered sequentially or concomitantly
are hampered by the fact that to date no trial has been
performed to evaluate this variable.
Recently, a meta-analysis of individual patient data7 failed
to show a statistically significant benefit of preoperative
radiotherapy alone on survival. Moreover, the most recent
large scale RCTs of preoperative chemotherapy as a single
adjuvant treatment showed conflicting results. Our meta-
analysis clearly shows that CRT as neoadjuvant treatment
improves survival. We speculate that chemotherapy enhances
the local effects of radiotherapy and thus decreases the
likelihood of spread from the primary tumour prior to
exposure of the patient to the tumour growth promoting
stimulus of surgery.
The results of this retrospective analysis are subject to
several limitations. Differences in the baseline severity of
illness in the population of the RCTs, in the irradiation
techniques, and in the chemoradiotherapy regimens may
limit the accuracy of this meta-analysis. These summary
results describe only between study, not between patient,
variation because they reflect group averages rather than
individual data. Lack of data on other potential confounders
such as size and location of the tumour could also affect the
accuracy of the results. The meta-analysis was performed
using summary data, and more detailed treatment compar-
isons could be achieved with a meta-analysis of individual
patient data.
Screening of the non-English literature, the extensive
manual and computer searches for studies, in addition to the
personal contacts made directly with principal investigators,
make us confident that no important published trials were
overlooked. Publication bias was probably not substantial
and considered unlikely to change the direction of our pooled
estimate of treatment effect. We should be particularly
concerned about publication bias in settings in which small
studies are being conducted.
Finally, the standard approach to inference for random
effects model used in this meta-analysis including few RCTs
can inflate the type I error rate.35
The available evidence is sufficient to conclude the
following: (1) preoperative CRT reduces the three year overall
mortality compared with surgery alone. The magnitude of the
overall effect is clinically relevant. Further large scale
multicentre RCTs may prove useful to substantiate the
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benefit on overall survival; (2) the magnitude of the
downstaging effect with CRT was large; and (3) postoperative
mortality was significantly increased by CRT. Studies
addressing strategies that could potentially reduce the
toxicity profile would have major implications for patients
affected by oesophageal cancer.
Further RCTs in patients with oesophageal cancer inves-
tigating the efficacy and safety of induction chemotherapy in
addition to preoperative chemoradiotherapy are underway by
the RTOG Gastrointestinal Cancer Committee.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
F Fiorica, Cattedra di Radioterapia Oncologica, University of Modena e
Reggio Emilia, Italy, and Servizio Radioterapia Oncologica, Azienda
Ospedaliera Sant’Anna University of Ferrara, Italy
D Di Bona, C Camma`, Cattedra e Unita` Operativa di Gastroenterologia
University of Palermo, Italy, and IBIM, Consiglio Nazionale delle
Ricerche, Palermo, Italy
F Schepis, Dipartimento di Medicina Interna, University of Modena and
Reggio Emilia, Italy
A Venturi, A M Falchi, Cattedra di Radioterapia Oncologica, University
of Modena e Reggio Emilia, Italy
A Licata, A Craxı`, Cattedra e Unita` Operativa di Gastroenterologia,
University of Palermo, Italy
L Shahied, Fox Chase Cancer Center, Philadelphia, PA, USA
REFERENCES
1 The World Health Report 1997. Geneva: World Health Organization, 1997.
2 Faivre J, Forman D, Esteve J, et al. Survival of patients with oesophageal and
gastric cancers in Europe. Eur J Cancer 1998;34:2167–75.
3 Kelsen DP, Bains M, Burt M. Neoadjuvant chemotherapy and surgery of
cancer of the esophagus. Semin Surg Oncol 1990;6:268–73.
4 Muller JM, Erasmi H, Stelzner M, et al. Surgical therapy of oesophageal
carcinoma. Br J Surg 1990;77:845–57.
5 Daily JM, Karnell LH, Menck HR. National Cancer Database report on
oesophageal carcinoma. Cancer 1996;78:1820–8.
6 Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic
resection compared with limited transhiatal resection for adenocarcinoma of
the esophagus. N Engl J Med 2002;347:1662–9.
7 Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for
oesophageal carcinoma (Cochrane Review). London: The Cochrane Library,
2003 (issue 4)).
8 Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery
compared with surgery alone for localized oesophageal cancer. N Engl J Med
1998;339:1979–84.
9 Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical
therapy alone for squamous cell carcinoma of the esophagus: a prospective
randomized trial. J Thorac Cardiovasc Surg 1997;114:210–17.
10 Kok TC, van Lanschot J, Siersema PD, for the Rotterdam Oesophageal Tumor
Study Group, et al. Neoadjuvant chemotherapy in operable oesophageal
squamous cell cancer: final report of a phase III multicenter randomized
controlled trial. Proc Am Soc Clin Oncol 1997;16:A984.
11 Medical Research Council Ooesophageal Cancer Working Party. Surgical
resection with or without preoperative chemotherapy in oesophageal cancer:
a randomised controlled trial. Lancet 2002;359:1727–33.
12 Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs
survival in operable oesophageal carcinoma: a randomized, multicenter study
of pre-operative radiotherapy and chemotherapy. The second Scandinavian
trial in oesophageal cancer. World J Surg 1992;16:1104–10.
13 Le Prise, E, Etienne PL, Meunier B, et al. A randomized study of
chemotherapy, radiation therapy, and surgery versus surgery for localized
squamous cell carcinoma of the esophagus. Cancer 1994;73:1779–84.
14 Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in
oesophageal cancer. Hepatogastroenterology 1994;41:391–3.
15 Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal
therapy and surgery for oesophageal adenocarcinoma. N Engl J Med
1996;335:462–7.
16 Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by
surgery compared with surgery alone in squamous-cell cancer of the
esophagus. N Engl J Med 1997;337:161–7.
17 Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative
chemoradiation versus surgery alone in patients with locoregional
oesophageal carcinoma. J Clin Oncol 2001;19:305–13.
18 Walsh TN, Noonan N, Hollywood D, et al. Multimodality therapy versus
surgery for oesophageal adenocarcinoma. A prospective randomised trial.
Gastroenterology 1996;110(suppl 4):A611.
19 Ackland S, Burmeisteister BH, Smithers BM, et al. Preoperative
chemoradiation (CT/RT) versus surgery alone for resectable carcinoma of
esophagus: an Australasian randomised study. Proc Am Soc Clin Oncol
1998;17:A1095.
20 Burmeister BH, Smithers BM, Fitzgerald L, et al. A randomized phase III trial of
preoperative chemoradiation followed by surgery (CR-S) versus surgery alone
(S) for localized resectable cancer of the esophagus. Proc Am Soc Clin Oncol
2002;20:A518.
21 Walsh TN, Noonan N, Hollywood D, et al. Multimodality therapy versus
surgery for oesophageal adenocarcinoma. A prospective randomised trial.
Gastroenterology 1995;108(suppl 4):A550.
22 Urba S, Orringer M, Turrisi A, et al. A randomized trial comparing surgery (S)
to preoperative concomitant chemoradiation plus surgery in patients (pts) with
resectable oesophageal cancer (CA): updated analysis. Pro Am Soc Clin
Oncol, 1997;16:A983.
23 Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of
meta-analyses of randomised controlled trials: the QUOROM statement.
Quality of Reporting of Meta-analyses. Lancet 1999;27:1896–900.
24 Nicolucci A, Grilli R, Alexanian AA, et al. Quality evolution and clinical
implications of randomized, controlled trials on the treatment of lung cancer:
A lost opportunity for meta-analysis. JAMA 1989;262:2101–7.
25 Ju¨ni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical
trials for meta-analysis. JAMA 1999;282:1054–60.
26 Esophagus. In:American Joint Committee on Cancer: AJCC cancer Staging
Manual, 5th edn., Philadelphia: Lippincott-Raven Publishers 1997:65–69, ;.
27 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials
1986;7:177–88.
28 Mantel N, Haenszel W. Statistical aspects of the analysis of data from
retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.
29 Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart
failure patient in sinus rhythm benefit from digoxin therapy? A systematic
overview and meta-analysis. Am J Med 1990;88:279–86.
30 Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for
normal tissue responses. Int J Radiat Oncol Biol Phys 1982;8:1981–7.
31 Hedges LV, Olkin I. Statistical methods for meta-analysis. New York:
Academic Press, 1985.
32 Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial
infarction: an overview of the randomized trials. Prog Cardiovasc Dis
1985;27:335–71.
33 Devesa SS, Blot WJ, Fraumeni JF jr. Changing patterns in the incidence of
esophageal and gastric carcinoma in the United States. Cancer
1998;83:2049–53.
34 Wayman J, Forman D, Griffin SM. Monitoring the changing pattern of
esophago-gastric cancer: data from a UK regional cancer registry. Cancer
Causes Control 2001;12:943–9.
35 Follman DA, Proschan MA. Valid inference in random effects meta-analysis.
Biometrics 1999;55:732–7.
Rev 7.51n/W (Jan 20 2003)
Gut gt25080 Module 1 21/4/04 16:47:24 Topics: 205; 172; 298; 299
6 Fiorica, Bona, Schepis, et al
www.gutjnl.com
Authors Queries
Journal: Gut
Paper: gt25080
Title: Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis
Dear Author
During the preparation of your manuscript for publication, the questions listed below have arisen. Please attend to these
matters and return this form with your proof. Many thanks for your assistance
Query
Reference
Query Remarks
1 For reference No 26, do you have
the names of the authors or edi-
tors?
Rev 7.51n/W (Jan 20 2003)
Gut gt25080 Module 1 21/4/04 16:47:24 Topics: 205; 172; 298; 299
Preoperative chemoradiotherapy for oesophageal cancer 7
www.gutjnl.com
